The FDA decision on Incyte Corp.s (INCY) Ruxolitinib cream, a selective JAK1/JAK2 inhibitor designed for topical application, as a treatment for atopic dermatitis, is expected on September 21.Atopic dermatitis, a type of eczema, is a chronic skin disease, affecting more than 21 million people in the United States. It is characterized by inflammation and intense itch. Patients with atopic dermatitis are also more susceptible to bacterial, viral and fungal infections.Ruxolitinib in oral formulation is approved by the FDA under brand name Jakafi for the treatment of Myelofibrosis, Polycythemia Vera, and Graft-versus-host disease.While there are a range of FDA-approved drugs for atopic dermatitis, no JAK inhibitor has yet been approved, either in an oral or topical formulation, for this indication.INCY closed Friday’s trading at $75.68, up 0.71%.